Q-omics provides the consensus-scored ABCA10 profile across patient tissues and cancer cell-line models. ABCA10 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ABCA10 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ABCA10 RNA expression shows 18,310 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, THCA, and LUAD as cancer lineages where ABCA10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABCA10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABCA10 survival associations across molecular data types. ABCA10 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABCA10 RNA expression–survival associations across cancer types. High ABCA10 expression shows unfavorable associations in LGG and THYM, but favorable associations in HNSC, BRCA, PAAD and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ABCA10 RNA expression.
This table summarizes ABCA10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ABCA10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABCA10 shows lower tumor expression in THCA, COAD, LUAD, LUSC, BRCA and UCEC. The THCA box plot shows higher ABCA10 RNA expression in normal versus tumor tissue (log2 FC = −1.106, t-test p < 0.001).
This table shows molecular features associated with ABCA10 in patient tissues and cancer cell lines. In patient samples, ABCA10 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ABCA10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
